Morgan Stanley Sarepta Therapeutics, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 953,104 shares of SRPT stock, worth $106 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

953,104

Previous 2,623,361 63.67%

Holding current value

$106 Million

Previous $414 Million 71.28%

% of portfolio

0.01%

Previous 0.03%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$124.33 - $156.75 $208 Million - $262 Million	-1,670,257 Reduced 63.67%	953,104 $119 Million
Q2 2024 Oct 17, 2024	BUY	$113.33 - $163.85 $197 Million - $284 Million	1,734,928 Added 195.28%	2,623,361 $414 Million
Q2 2024 Aug 14, 2024	BUY	$113.33 - $163.85 $197 Million - $284 Million	1,734,928 Added 195.28%	2,623,361 $414 Million
Q1 2024 Oct 17, 2024	SELL	$93.7 - $141.53 $163 Million - $246 Million	-1,734,928 Reduced 66.13%	888,433 $115 Million
Q1 2024 Aug 16, 2024	SELL	$93.7 - $141.53 $46.1 Million - $69.6 Million	-491,716 Reduced 35.63%	888,433 $115 Million
Q1 2024 May 15, 2024	SELL	$93.7 - $141.53 $46.1 Million - $69.6 Million	-491,716 Reduced 35.63%	888,433 $115 Million
Q4 2023 Aug 16, 2024	SELL	$67.31 - $124.76 $83.7 Million - $155 Million	-1,243,212 Reduced 47.39%	1,380,149 $133 Million
Q4 2023 Feb 13, 2024	BUY	$67.31 - $124.76 $35.3 Million - $65.5 Million	524,705 Added 61.34%	1,380,149 $133 Million
Q3 2023 Nov 15, 2023	SELL	$102.5 - $123.59 $12.4 Million - $14.9 Million	-120,906 Reduced 12.38%	855,444 $104 Million
Q2 2023 Aug 14, 2023	BUY	$106.4 - $157.19 $9.24 Million - $13.7 Million	86,844 Added 9.76%	976,350 $112 Million
Q1 2023 May 15, 2023	BUY	$117.53 - $155.99 $50.8 Million - $67.5 Million	432,453 Added 94.62%	889,506 $123 Million
Q4 2022 Feb 14, 2023	BUY	$100.86 - $132.13 $6.13 Million - $8.03 Million	60,786 Added 15.34%	457,053 $59.2 Million
Q3 2022 Nov 14, 2022	SELL	$75.71 - $119.24 $1.62 Million - $2.56 Million	-21,439 Reduced 5.13%	396,267 $43.8 Million
Q2 2022 Oct 27, 2022	BUY	$62.69 - $88.44 $2.96 Million - $4.17 Million	47,190 Added 12.74%	417,706 $31.3 Million
Q2 2022 Aug 15, 2022	BUY	$62.69 - $88.44 $2.96 Million - $4.17 Million	47,190 Added 12.74%	417,706 $31.3 Million
Q1 2022 Oct 27, 2022	SELL	$63.15 - $90.42 $2.98 Million - $4.27 Million	-47,190 Reduced 11.3%	370,516 $28.9 Million
Q1 2022 May 13, 2022	BUY	$63.15 - $90.42 $8.4 Million - $12 Million	133,013 Added 56.0%	370,516 $28.9 Million
Q4 2021 Feb 14, 2022	SELL	$77.28 - $99.42 $7.86 Million - $10.1 Million	-101,766 Reduced 30.0%	237,503 $21.4 Million
Q3 2021 Nov 15, 2021	BUY	$65.97 - $92.48 $22.4 Million - $31.4 Million	339,269 New	339,269 $31.4 Million

Others Institutions Holding SRPT

# of Institutions

531

Shares Held

84.5M

Call Options Held

2.06M

Put Options Held

1.52M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $9.71B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account